Amended Quarterly Report (10-q/a)
February 25 2015 - 3:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
QUARTERLY REPORT UNDER SECTION 13 OR
15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended: December
31, 2014
Commission File Number: 001-36081
NANOVIRICIDES, INC.
(Exact name of Company as specified in
its charter)
NEVADA |
76-0674577 |
(State or other jurisdiction) |
(IRS Employer Identification No.) |
of incorporation or organization) |
|
135 Wood Street, Suite 205
West Haven, Connecticut 06516
(Address of principal executive offices
and zip code)
(203) 937-6137
(Company’s telephone number, including
area code)
Indicate by check mark whether the Company
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the Company was required to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes x No ¨
Indicate by check mark whether the Company
has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the Company was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act.
Large accelerated filer |
¨ |
Accelerated filer |
¨ |
Non-accelerated filer |
x |
Smaller reporting company |
¨ |
Indicate by check mark whether the Company
is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No x
The number of shares outstanding of the
Company’s Common Stock as of February 24, 2015 was approximately: 56,564,190.
Explanatory
Note
The sole purpose of this Amendment to NanoViricides,
Inc.’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2014, originally filed with the Securities
and Exchange Commission on February 24, 2015 (the “Form 10-Q”), is to provide the consolidated financial statements
and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language) to furnish Exhibit 101 to the Form
10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and
related notes from the Form 10-Q formatted in XBRL. No other changes have been made to the Form 10-Q.
ITEM 6. EXHIBITS.
Exhibit Number |
Description of Exhibits |
|
|
31.1 |
Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer * |
|
|
31.2 |
Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer * |
|
|
32.1 |
Section 1350 Certification of Chief Executive Officer * |
|
|
32.2 |
Section 1350 Certification of Chief Financial Officer * |
|
|
101.INS |
XBRL Instance Document** |
|
|
101.SCH |
XBRL Taxonomy Extension Schema Document** |
|
|
101.CAL |
XBRL Taxonomy Extension Calculation Linkbase Document** |
|
|
101.DEF |
XBRL Taxonomy Extension Definition Linkbase Document** |
|
|
101.LAB |
XBRL Taxonomy Extension Label Linkbase Document** |
|
|
101.PRE |
XBRL Taxonomy Extension Presentation Linkbase Document** |
| * | These exhibits were previously included or incorporated
by reference in NanoViricides, Inc.’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2014, filed
with the Securities and Exchange Commission on February 24, 2015. |
SIGNATURES
Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
NANOVIRICIDES, INC. |
|
|
|
|
|
/s/ Eugene Seymour, M.D. |
Dated: February 25, 2015 |
Name: Eugene Seymour, M.D. |
|
Title: Chief Executive Officer and Director |
|
(Principal Executive Officer ) |
|
|
|
|
|
/s/ Meeta Vyas |
Dated: February 25, 2015 |
Name: Meeta Vyas |
|
Title: Chief Financial Officer |
|
(Principal Financial Officer) |
EXHIBIT INDEX
Exhibit Number |
Description of Exhibits |
|
|
31.1 |
Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer* |
|
|
31.2 |
Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer* |
|
|
32.1 |
Section 1350 Certification of Chief Executive Officer* |
|
|
32.2 |
Section 1350 Certification of Chief Financial Officer* |
|
|
101.INS |
XBRL Instance Document** |
|
|
101.SCH |
XBRL Taxonomy Extension Schema Document** |
|
|
101.CAL |
XBRL Taxonomy Extension Calculation Linkbase Document** |
|
|
101.DEF |
XBRL Taxonomy Extension Definition Linkbase Document** |
|
|
101.LAB |
XBRL Taxonomy Extension Label Linkbase Document** |
|
|
101.PRE |
XBRL Taxonomy Extension Presentation Linkbase Document** |
| * | These exhibits were previously included or incorporated
by reference in NanoViricides, Inc.’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2014, filed
with the Securities and Exchange Commission on February 24, 2015. |
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2023 to Sep 2024